Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SANOFI : Gets a Buy rating from JP Morgan

12/01/2021 | 09:41am EST

Already positive, the research from JP Morgan and its analyst Richard Vosser still consider the stock as a Buy opportunity. The target price remains set at EUR 105.


ę MarketScreener with dpa-AFX Analyser 2021
All news about SANOFI
07:39aRegeneron, Sanofi Pull FDA Application for Libtayo in Advanced Cervical Cancer
DJ
07:35aRegeneron, Sanofi Withdraw Application for Libtayo as Treatment of Advanced Cervical Ca..
MT
07:33aRegeneron, Sanofi withdraw FDA application for cancer drug's expanded use
RE
07:09aRegeneron, Sanofi withdraw FDA application for Libtayo use in cervical cancer
RE
05:51aSANOFI : Deutsche Bank reiterates its Sell rating
MD
01/27European ADRs Move Higher in Thursday Trading
MT
01/27SANOFI : Goldman Sachs remains its Buy rating
MD
01/26SANOFI : JP Morgan reiterates its Buy rating
MD
01/26Business investment into Singapore dropped 31% in 2021
RE
01/26Business investment into Singapore dropped 31% in 2021
RE
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 790 M 42 136 M 42 136 M
Net income 2021 6 141 M 6 847 M 6 847 M
Net Debt 2021 9 936 M 11 079 M 11 079 M
P/E ratio 2021 19,5x
Yield 2021 3,48%
Capitalization 118 B 132 B 132 B
EV / Sales 2021 3,39x
EV / Sales 2022 3,11x
Nbr of Employees 99 412
Free-Float -
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 94,89 €
Average target price 107,27 €
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI7.12%132 839
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960